Menu

Category: Europe

Will Europe Miss The Boat On ATMPs?

Europe is lagging behind in the adoption of ATMPs, as seen in its low profitability and R&D spending compared to other regions. This is largely due to the challenges faced in clinical assessments of ATMPs and the need for innovative pricing and reimbursement pathways to ensure early patient access.

Read More »
The Trump Effect on Pharmaceutical Company Stock Prices and their effect on drug prices

Drug Pricing – Feeling the Squeeze

Whatever happens next in the US and elsewhere, life science companies must take charge and own the value story behind their innovative products. It starts by understanding and mastering value assessment frameworks. An Inbeeo thought experiment.

Read More »

Get started with Inbeeo and realise the true value of your assets.